Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
| ▸ | METAP2 | P50579 | 1/20 | 0.55 |
| ▸ | METAP1 | P53582 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 4/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | BRD4 | O60885 | 1/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13668122 | 0.99 | KDM4E (0.61) | KDM4EHSD17B10MAPTNPSR1METAP2 | |
| SCHEMBL9622563 | 0.82 | METAP2 (0.65) | KDM4EHSD17B10MAPTNPSR1METAP2 | |
| SCHEMBL8266375 | 0.82 | KDM4E (0.66) | KDM4EHSD17B10MAPTNPSR1METAP2 | |
| SCHEMBL4185155 | 0.81 | KDM4E (0.62) | KDM4EHSD17B10MAPTMAPK1MEN1 | |
| SCHEMBL13668143 | 0.81 | L3MBTL1 (0.62) | KDM4EHSD17B10ALDH1A1TSHR | |
| SCHEMBL4175538 | 0.80 | KDM4E (0.64) | KDM4EHSD17B10MAPTMAPK1MEN1 | |
| SCHEMBL4190070 | 0.80 | KDM4E (0.60) | KDM4EHSD17B10MAPTNPSR1METAP2 | |
| SCHEMBL13668158 | 0.79 | HPGD (0.56) | KDM4EHSD17B10MAPTALDH1A1LMNA | |
| SCHEMBL9622725 | 0.79 | METAP2 (0.68) | KDM4EHSD17B10MAPTNPSR1METAP2 | |
| SCHEMBL13668124 | 0.79 | MEN1 (0.51) | KDM4EHSD17B10NPSR1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090264384-A1 | INDOLE, BENZIMIDAZOLE, AND BENZOLACTAM BORONIC ACID COMPOUNDS, ANALOGS THEREOF AND METHODS OF USE THEREOF | NUADA, INC. (US) | 2009-10-22 | — | — | US | claimed |
| US-20090005344-A1 | Compounds and Methods of Use Thereof | NKUADA, LLC (US) | 2009-01-01 | — | — | US | claimed |
| WO-2007134169-A9 | INDOLE, BENZIMIDAZOLE, AND BENZOLACTAM BORONIC ACID COMPOUNDS, ANALOGS THEREOF AND METHODS OF USE THEREOF | NUADA LLC (US) | 2008-07-24 | — | — | WO | claimed |
| US-20090264384-A1 | INDOLE, BENZIMIDAZOLE, AND BENZOLACTAM BORONIC ACID COMPOUNDS, ANALOGS THEREOF AND METHODS OF USE THEREOF | NUADA, INC. (US) | 2009-10-22 | — | — | US | disclosed |
| US-20090264384-A1 | INDOLE, BENZIMIDAZOLE, AND BENZOLACTAM BORONIC ACID COMPOUNDS, ANALOGS THEREOF AND METHODS OF USE THEREOF | NUADA, INC. (US) | 2009-10-22 | — | — | US | disclosed |
| US-20090264384-A1 | INDOLE, BENZIMIDAZOLE, AND BENZOLACTAM BORONIC ACID COMPOUNDS, ANALOGS THEREOF AND METHODS OF USE THEREOF | NUADA, INC. (US) | 2009-10-22 | — | — | US | disclosed |
| US-20090005344-A1 | Compounds and Methods of Use Thereof | NKUADA, LLC (US) | 2009-01-01 | — | — | US | disclosed |
| US-20090005344-A1 | Compounds and Methods of Use Thereof | NKUADA, LLC (US) | 2009-01-01 | — | — | US | disclosed |
| US-20090005344-A1 | Compounds and Methods of Use Thereof | NKUADA, LLC (US) | 2009-01-01 | — | — | US | disclosed |
| WO-2007134169-A9 | INDOLE, BENZIMIDAZOLE, AND BENZOLACTAM BORONIC ACID COMPOUNDS, ANALOGS THEREOF AND METHODS OF USE THEREOF | NUADA LLC (US) | 2008-07-24 | — | — | WO | disclosed |
| WO-2006050053-A2 | COMPOUNDS AND METHODS OF USE THEREOF | NUADA, LLC (US) | 2006-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090005344-A1 | Compounds and Methods of Use Thereof | TNF, IL1B, TNFRSF1A | KDM4E 3858/4885HSD17B10 3385/4885MAPT 3106/4885 |
| US-20090264384-A1 | INDOLE, BENZIMIDAZOLE, AND BENZOLACTAM BORONIC ACID COMPOUNDS, ANALOGS THEREOF AND METHODS OF USE THEREOF | TNF, NFKBIA, IL6 | KDM4E 2408/4885HSD17B10 3783/4885MAPT 1468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.